文献速递免疫规划

20价肺炎球菌结合疫苗在婴儿期接种13价结合疫苗的健康幼儿中的3期研究

A phase 3 study of 20-valent pneumococcal conjugate vaccine in healthy toddlers previously vaccinated in infancy with 13-valent pneumococcal conjugate vaccine.
PubMed 文献 · Vaccine · 2025-03-12

这项3期随机部分双盲研究评估了20价肺炎球菌结合疫苗(PCV20)在≥12-<24月龄、婴儿期已接种2剂13价结合疫苗(PCV13)的健康幼儿中的安全性、耐受性和免疫原性。356名参与者随机接受1剂或2剂PCV20或1剂PCV13。单剂PCV20后,除血清型12F(54.6%)外,≥75.9%的参与者对7个额外血清型IgG浓度≥0.35 μg/mL;2剂PCV20后该比例≥91.2%。PCV20安全性特征与PCV13相似。

要点

  • 单剂PCV20后,除12F型(54.6%)外,≥75.9%幼儿对7个额外血清型IgG≥0.35 μg/mL。
  • 2剂PCV20后,对7个额外血清型IgG≥0.35 μg/mL的比例≥91.2%。
  • PCV20安全性特征与PCV13相似。

核心结论

  • 在婴儿期接种2剂PCV13后,幼儿单剂PCV20可对7个额外血清型产生预期有助于提供保护的免疫应答,并对13个匹配血清型提供与PCV13相似的免疫保护。
  • 这些数据支持在幼儿剂次中将PCV13过渡为PCV20。
  • PCV20的安全性和耐受性特征与PCV13相似。

研究设计与样本

  • 3期、随机、部分双盲研究,纳入≥12-<24月龄、婴儿期已接种2剂PCV13的健康幼儿。
  • 参与者随机接受1剂或2剂PCV20(第2剂在第1剂后56-70天接种)或1剂PCV13。
  • 共356名参与者随机分组:2剂PCV20组n=121,1剂PCV20组n=118,PCV13组n=117。
  • 主要肺炎球菌免疫原性终点为末次接种后1个月时,对7个额外血清型达到预设血清型特异性IgG浓度(≥0.35 μg/mL)的参与者百分比。
  • 安全性终点包括局部反应、全身事件、不良事件和严重不良事件。

主要发现

  • 单剂PCV20后1个月,除血清型12F(54.6%)外,≥75.9%的参与者对全部7个额外血清型IgG浓度≥0.35 μg/mL。
  • 2剂PCV20后,对7个额外血清型IgG浓度≥0.35 μg/mL的参与者百分比≥91.2%。
  • PCV20对全部20个血清型(包括血清型12F)均引发IgG和OPA应答。
  • 对7个额外血清型,PCV20组的IgG分布与PCV13组区分良好且 substantially higher;对13个匹配血清型,各组间IgG分布总体相似。

关键数值与推荐

  • 单剂PCV20后,除血清型12F(54.6%)外,≥75.9%的参与者对7个额外血清型IgG浓度≥0.35 μg/mL。
  • 2剂PCV20后,对7个额外血清型IgG浓度≥0.35 μg/mL的参与者百分比≥91.2%。

临床怎么用

  • 原文结论指出这些数据支持在幼儿剂次中将PCV13过渡为PCV20。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This phase 3, randomized, partially double-blind study investigated the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine (PCV20) in healthy toddlers ≥12-<24 months of age who had previously received 2 infant doses of 13-valent PCV (PCV13). Participants were randomized to receive 1 or 2 doses of PCV20 (the second dose was administered 56-70 days after the first dose), or 1 dose of PCV13. The primary pneumococcal immunogenicity endpoint was the percentages of participants with predefined serotype-specific immunoglobulin G (IgG) concentrations (≥0.35 μg/mL) for the 7 additional serotypes 1 month after the last vaccination. Percentages of participants with predefined IgG concentrations for the 13 matched serotypes, IgG geometric mean concentrations, and opsonophagocytic activity (OPA) geometric mean titers were also evaluated for all 20 vaccine serotypes. Safety endpoints included local reactions, systemic events, adverse events, and serious adverse events. Overall, 356 participants were randomized (2-dose PCV20, n = 121; 1-dose PCV20, n = 118; PCV13, n = 117). One month after 1 PCV20 dose, ≥75.9 % of participants had IgG concentrations ≥0.35 μg/mL for all 7 additional serotypes, except serotype 12F (54.6 %). After 2 PCV20 doses, the percentage of participants with IgG concentrations ≥0.35 μg/mL for the 7 additional serotypes was ≥91.2 %. PCV20 elicited IgG and OPA responses for all 20 serotypes including serotype 12F. IgG distributions were well differentiated and substantially higher in PCV20 groups than the PCV13 group for the 7 additional serotypes, and generally similar between all groups for the 13 matched serotypes. In conclusion, a single toddler dose of PCV20 after 2 infant PCV13 doses elicited immune responses expected to help provide protection against the 7 additional serotypes and to provide similar protection against the 13 matched serotypes as PCV13. These data support a transition from PCV13 to PCV20 at the toddler dose. The safety and tolerability profile of PCV20 was similar to PCV13. Trial registration:Clinicaltrials.gov, NCT05408429.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Martinón-Torres F, Martinez SN, Kline MJ, et al. A phase 3 study of 20-valent pneumococcal conjugate vaccine in healthy toddlers previously vaccinated in infancy with 13-valent pneumococcal conjugate vaccine. Vaccine. 2025. PMID: 40081152. doi:10.1016/j.vaccine.2025.126931

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。